» Articles » PMID: 25533893

Experience of Adjunctive Cannabis Use for Chronic Non-cancer Pain: Findings from the Pain and Opioids IN Treatment (POINT) Study

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2014 Dec 24
PMID 25533893
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is increasing debate about cannabis use for medical purposes, including for symptomatic treatment of chronic pain. We investigated patterns and correlates of cannabis use in a large community sample of people who had been prescribed opioids for chronic non-cancer pain.

Methods: The POINT study included 1514 people in Australia who had been prescribed pharmaceutical opioids for chronic non-cancer pain. Data on cannabis use, ICD-10 cannabis use disorder and cannabis use for pain were collected. We explored associations between demographic, pain and other patient characteristics and cannabis use for pain.

Results: One in six (16%) had used cannabis for pain relief, 6% in the previous month. A quarter reported that they would use it for pain relief if they had access. Those using cannabis for pain on average were younger, reported greater pain severity, greater interference from and poorer coping with pain, and more days out of role in the past year. They had been prescribed opioids for longer, were on higher opioid doses, and were more likely to be non-adherent with their opioid use. Those using cannabis for pain had higher pain interference after controlling for reported pain severity. Almost half (43%) of the sample had ever used cannabis for recreational purposes, and 12% of the entire cohort met criteria for an ICD-10 cannabis use disorder.

Conclusions: Cannabis use for pain relief purposes appears common among people living with chronic non-cancer pain, and users report greater pain relief in combination with opioids than when opioids are used alone.

Citing Articles

Effect of cannabis use history on postoperative opioid utilization in lumbar fusion patients: an American retrospective study.

Mirpuri P, Khalid S, King P, Roy J, Elsamadicy A, Mehta A Asian Spine J. 2024; 18(5):639-646.

PMID: 39434224 PMC: 11538822. DOI: 10.31616/asj.2024.0194.


Experiences and Perceptions of Medical Cannabis among People Living with Chronic Pain and Community Pharmacists: A Qualitative Study in Canada.

Dassieu L, Paul-Savoie E, Develay E, Villela Guilhon A, Guenette L, Perreault K Can J Pain. 2023; 7(1):2258537.

PMID: 38027232 PMC: 10653616. DOI: 10.1080/24740527.2023.2258537.


Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions.

Bell A, MacCallum C, Margolese S, Walsh Z, Wright P, Daeninck P Cannabis Cannabinoid Res. 2023; 9(2):669-687.

PMID: 36971587 PMC: 10998028. DOI: 10.1089/can.2021.0156.


The association between cannabis and codeine use: a nationally representative cross-sectional study in Canada.

Garg R, Shojania K, De Vera M J Cannabis Res. 2022; 4(1):49.

PMID: 36085170 PMC: 9463740. DOI: 10.1186/s42238-022-00160-x.


Real-Time Monitoring of Cannabis and Prescription Opioid Co-Use Patterns, Analgesic Effectiveness, and the Opioid-Sparing Effect of Cannabis in Individuals With Chronic Pain.

Mun C, Nordeck C, Anderson Goodell E, Vandrey R, Zipunnikov V, Dunn K J Pain. 2022; 23(11):1799-1810.

PMID: 35817255 PMC: 9938711. DOI: 10.1016/j.jpain.2022.06.009.